IMRT 2018
… Benefit of Androgen Deprivation - EORTC Trial 22991
Phase 3 trial showing benefit
Six months of concomitant and adjuvant AD
Improves biochemical and clinical DFS of intermediate and high- risk cT1b-c to cT2a
13% gain in 5 year PSA control
Bolla 2016
Made with FlippingBook - professional solution for displaying marketing and sales documents online